Emilien Bernard

Dr. Emilien Bernard

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2015 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
AFAxel Freischmidt
Axel Freischmidt
TWThomas Wieland
Thomas Wieland
BRBenjamin Richter
Benjamin Richter
WRWolfgang Ruf
Wolfgang Ruf
VSVeronique Schaeffer
Veronique Schaeffer
JWJochen H Weishaupt
Jochen H Weishaupt

1 March 2018 in Neuron
Verified
Journal Article
Closed access
ANAude Nicolas
Aude Nicolas
KKKevin P. Kenna
Kevin P. Kenna
ARAlan E. Renton
Alan E. Renton
NTNicola Ticozzi
Nicola Ticozzi
FFFaraz Faghri
Faraz Faghri
NTNatalie A. Twine
Natalie A. Twine

1 August 2018 in iScience
Verified
Journal Article
Open access
LSLucie Sauzéat
Lucie Sauzéat
EBEmilien Bernard
Emilien Bernard
APArmand Perret-Liaudet
Armand Perret-Liaudet
IQIsabelle QUADRIO
Isabelle QUADRIO
AVAlain Vighetto
Alain Vighetto
VBVincent Balter
Vincent Balter
Redox-active metals are thought to be implicated in neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). To address this point, we measured the concentrations of 12 elements and, for the first time, the stable isotope compositions of copper (redox-active) and zinc (redox-inactive) in human cerebrospinal fluids of 31 patients with ALS, 11 age-matched controls (CTRL), and 14 patients with Alzheimer disease. We first show that metal concentrations weakly discriminate patients with ALS from the two other groups. We then report that zinc isotopic compositions are similar in the three groups, but that patients with ALS have significantly 65copper-enriched isotopic compositions relative to CTRL and patients with AD. This result unambiguously demonstrates that copper is implicated in ALS. We suggest that this copper isotopic signature may result from abnormal protein aggregation in the brain parenchyma, and propose that isotopic analysis is a potential tool that may help unraveling the molecular mechanisms at work in ALS.

Verified
Journal Article
Open access
PDF file
EBEmilien Bernard
Emilien Bernard
APAntoine Pegat
Antoine Pegat
JSJuliette Svahn
Juliette Svahn
FBFrançoise Bouhour
Françoise Bouhour
Pascal LeblancPascal Leblanc
Pascal Leblanc
Kévin MouzatKévin Mouzat
Kévin Mouzat
Mutations in the copper zinc superoxide dismutase 1 (SOD1) gene are the second most frequent cause of familial amyotrophic lateral sclerosis (ALS). Nearly 200 mutations of this gene have been described so far. We report all SOD1 pathogenic variants identified in patients followed in the single ALS center of Lyon, France, between 2010 and 2020. Twelve patients from 11 unrelated families are described, including two families with the not yet described H81Y and D126N mutations. Splice site mutations were detected in two families. We discuss implications concerning genetic screening of SOD1 gene in familial and sporadic ALS.

12 March 2019 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
LCLaurent Coudert
Laurent Coudert
TNTakashi Nonaka
Takashi Nonaka
EBEmilien Bernard
Emilien Bernard
MHMasato Hasegawa
Masato Hasegawa
LSLaurent Schaeffer
Laurent Schaeffer
Pascal LeblancPascal Leblanc
Pascal Leblanc

5 January 2013 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
EOElodie Ong
Elodie Ong
LMLaura Mechtouff
Laura Mechtouff
EBEmilien Bernard
Emilien Bernard
TCTae-Hee Cho
Tae-Hee Cho
LDLansana Laho Diallo
Lansana Laho Diallo
LDLaurent Derex
Laurent Derex